BCC patients with BCC-associated STR somatic mutations in BRAF or APC show more marked overexpression of the hedgehog signaling pathway (see Figure 9) and so are more likely to respond to hedgehog (Hh) inhibitors like Vesmodigib or Sonidegib, which are currently used [27,28,29,30,31]. This evidence concerns the gene BRAF and skin basal cell carcinoma.